Lakewood, NJ, May 06, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (NASDAQ: EZRA) (“Reliance” or the “Company”), announced today that it will host a conference call Thursday, May 7, 2026, at 4:30 PM Eastern Time to discuss financial results for the first quarter 2026 and provide a business update.
A webcast replay will be available on the investor relations section of the Company’s website at https://relianceglobalgroup.com/events-and-presentations/ through May 7, 2027. A telephone replay of the call will be available approximately one hour following the call, through May 21, 2026, and can be accessed by dialing +1 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering access code 53992.
About Reliance Global Group, Inc.
Reliance Global Group, Inc. (NASDAQ: EZRA) is an InsurTech pioneer, leveraging artificial intelligence (AI), and cloud-based technologies, to transform and improve efficiencies in the insurance agency/brokerage industry. The Company’s business-to-business InsurTech platform, RELI Exchange, provides independent insurance agencies an entire suite of business development tools, enabling them to effectively compete with large-scale national insurance agencies, whilst reducing back-office cost and burden. The Company’s business-to-consumer platform, 5minuteinsure.com, utilizes AI and data mining, to provide competitive online insurance quotes within minutes to everyday consumers seeking to purchase auto, home, and life insurance. In addition, the Company operates its own portfolio of select retail “brick and mortar” insurance agencies which are leaders and pioneers in their respective regions throughout the United States, offering a wide variety of insurance products.
In addition to its insurance and Insurtech operations, Reliance operates EZRA International Group, its strategic growth platform focused on identifying, acquiring, and building majority or controlling stakes in high-growth technology companies. EZRA International Group is designed to complement Reliance’s core insurance business by expanding market reach and supporting long-term shareholder value creation through disciplined capital allocation and active ownership.
LifeSci Global Launches as Reliance’s Life Sciences Platform, Partnering with Scott Korman and David Turner as Its Founding Operator-Partners to Build, Lead and Grow the Platform
Korman and Turner Bring Complementary Decades of Private Equity, Capital Markets, Healthcare and Company-Building Expertise to Anchor the Platform; Innervate Provides Exposure to Estimated $250 Million Neuroblastoma Opportunity, Potential Expansion Opportunities in Additional Disease Areas and Priority Review Voucher Upside
LAKEWOOD, N.J., May 05, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: EZRA) (“we,” “us,” “our,” the “Company” or “Reliance”) today announced the formal launch of LifeSci Global Group LLC (“LifeSci Global”), its dedicated life sciences and biotechnology platform, co-founded alongside Scott Korman and David Turner, who will serve as the platform’s founding operator-partners and lead all aspects of its build-out and growth. LifeSci Global is a subsidiary of EZRA International Group, Reliance’s strategic growth platform focused on building and investing in high-growth technology and life sciences companies. In connection with this launch, Reliance is also announcing Innervate Radiopharmaceuticals as LifeSci Global’s first platform investment.
The launch of LifeSci Global reflects Reliance’s studio model: rather than making passive investments, Reliance identifies compelling verticals, launches a dedicated platform, and partners with exceptional proven operators who possess the domain expertise to build great companies from the ground up. Scott Korman and David Turner are those operators for the life sciences vertical. They bring complementary capabilities spanning private equity, capital markets, healthcare strategy and company formation, and will be responsible for identifying, building and managing companies within LifeSci Global – beginning with Innervate Radiopharmaceuticals.
LifeSci Global was co-founded in connection with strategic investment in Innervate Radiopharmaceuticals, a developer of positron emission tomography (PET) imaging and a therapeutic focused initially on neuroblastoma and broader future applications in cardiovascular and neurodegenerative diseases. As the platform’s first investment, Innervate exemplifies the type of company LifeSci Global was built to identify and advance: differentiated science, a significant unmet medical need, and a clear path toward development and commercial milestones. Mr. Korman currently serves as Chief Executive Officer of Innervate and as a member of Reliance Global Group’s Board of Directors, ensuring direct continuity between the Company’s governance, LifeSci Global’s strategic mandate and the execution of the platform’s first investment. Mr. Turner serves as Chief Operating Officer of Innervate Radiopharmaceuticals, where he is the driver behind the company’s radiopharmaceutical development program, ensuring that LifeSci Global’s platform expertise is directly embedded in the execution of its first investment.
Reliance believes that the selection of Mr. Korman and Mr. Turner as LifeSci Global’s founding operator-partners is the central strategic decision underlying the platform’s launch. Under Reliance’s studio model, platforms succeed by anchoring each vertical with operators who have the proven track records, industry relationships and judgment to build and scale companies from the ground up. LifeSci Global is designed with that principle at its core – and Messrs. Korman and Turner are its embodiment. Together, they will be responsible for sourcing and building LifeSci Global’s portfolio, supporting each company through its development lifecycle, and deploying their combined expertise across private equity, capital markets, healthcare strategy and operational execution to drive long-term value creation.
“The launch of LifeSci Global is a significant milestone for Reliance and EZRA International Group,” said Ezra Beyman, Chairman and Chief Executive Officer of Reliance Global Group. “We built this platform around a simple conviction: the right operators make all the difference. Scott and David are proven, deeply experienced practitioners who will roll up their sleeves and build companies. That is the LifeSci Global model, and we believe it is a differentiated approach to value creation in life sciences.”
Mr. Korman brings more than four decades of experience as a private equity principal, entrepreneur and operator, and is central to LifeSci Global’s strategy as its founding operator-partner. Over the course of his career, he has led acquisitions, corporate turnarounds and growth-stage businesses across a range of industries, raised significant capital, and served in executive and board roles across both public and private companies. His experience spans the full lifecycle of company development, from early-stage investment and strategic planning through scaling, operational execution and corporate governance. Critically, Mr. Korman is an active builder. His current role as Chief Executive Officer of Innervate Radiopharmaceuticals demonstrates his hands-on approach and his ability to lead a company through late-stage development with the rigor and conviction required to reach commercialization. His simultaneous role on Reliance’s Board of Directors ensures that LifeSci Global’s strategy is directly connected to Reliance’s governance and capital allocation framework.
Mr. Turner brings more than 25 years of experience in global capital markets and is the second pillar of LifeSci Global’s operator-partner model. His career includes senior roles at JPMorgan, Lehman Brothers and Macquarie Bank – institutions synonymous with sophisticated capital formation and cross-border advisory at the highest levels. Throughout his career, he has advised institutional investors and companies on capital formation, cross-border strategy and market positioning, with particular depth across healthcare and life sciences. His experience across the United States, Asia and Israel gives LifeSci Global a global perspective as the platform sources and evaluates emerging biotechnology, diagnostics and life sciences opportunities. Mr. Turner’s ability to structure and access capital across markets is expected to be a meaningful advantage as LifeSci Global advances portfolio companies through development, financing and strategic inflection points.
Together, Mr. Korman and Mr. Turner represent a purpose-built partnership for the life sciences vertical. Their complementary backgrounds – Mr. Korman’s decades of operational and entrepreneurial experience and Mr. Turner’s global capital markets expertise with a healthcare focus – are designed to give LifeSci Global the capability to identify high-potential companies, build them from the ground up, structure disciplined transactions and support portfolio companies through the full arc of development, regulatory, financing and commercialization milestones. As founding operator-partners, they will be actively engaged at every stage of LifeSci Global’s portfolio as active builders, and not simply as advisors.
“In life sciences, the quality of the team is the platform,” said Moshe Fishman, Senior Vice President of Strategic Ventures at Reliance Global Group. “Scott’s track record as an operator and entrepreneur across four decades, combined with David’s exceptional capital markets network and healthcare expertise built at JPMorgan, Lehman Brothers and Macquarie, gives LifeSci Global a foundation that we believe is strong and well-positioned. They are here to build companies, and we believe that hands-on approach is the right one for this platform.”
With LifeSci Global now launched and anchored by Scott Korman and David Turner, the platform is actively evaluating additional life sciences and biotechnology opportunities. LifeSci Global’s first platform investment, Innervate Radiopharmaceuticals, provides Reliance with exposure to a late-stage radiopharmaceutical platform targeting a serious unmet need in pediatric oncology. Innervate’s lead asset, 18F-mFBG, is being developed as a next-generation PET imaging agent for neuroblastoma, with potential future applications in cardiovascular and neurodegenerative diseases. Reliance believes Innervate’s initial neuroblastoma indication represents an estimated market opportunity of approximately $250 million The Company also believes Innervate may have potential additional significant expansion opportunities [based on [source/Company internal estimates]] in cardiovascular and neurodegenerative disease, as well as potential Priority Review Voucher upside if regulatory approval is ultimately obtained and a voucher is awarded. Under the stewardship of Mr. Korman as Chief Executive Officer, Innervate represents the first example of LifeSci Global’s operator-led model in action.
About Reliance Global Group, Inc.
Reliance Global Group, Inc. (NASDAQ: EZRA) is an InsurTech pioneer leveraging artificial intelligence (AI) and cloud-based technologies to transform and improve efficiencies in the insurance agency and brokerage industry. The Company’s business-to-business InsurTech platform, RELI Exchange, provides independent insurance agencies with a full suite of business development tools, enabling them to compete effectively with large-scale national insurance agencies while reducing back-office costs and burden. The Company’s business-to-consumer platform, 5minuteinsure.com, uses AI and data mining to provide competitive online insurance quotes within minutes to everyday consumers seeking to purchase auto, home, and life insurance. In addition, the Company operates its own portfolio of select retail brick-and-mortar insurance agencies, which are leaders and pioneers in their respective regions throughout the United States and offer a wide variety of insurance products.
In addition to its insurance and Insurtech operations, Reliance operates EZRA International Group, its strategic growth platform focused on identifying, acquiring, and building majority or controlling stakes in high-growth technology and life sciences companies. EZRA International Group is designed to complement Reliance’s core insurance business by expanding market reach and supporting long-term shareholder value creation through disciplined capital allocation and active ownership.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, without limitation, statements regarding: the launch of LifeSci Global Group LLC and its strategy, structure and operator-partner model; the roles, responsibilities and expected contributions of Scott Korman and David Turner as founding operator-partners of LifeSci Global; the Company’s investment in Innervate Radiopharmaceuticals and the expected benefits thereof; the development, regulatory pathway, clinical progress and commercialization potential of Innervate’s product candidates, including 18F-mFBG, for neuroblastoma and potential future indications in cardiovascular and neurodegenerative diseases; the potential for Innervate to receive a Rare Pediatric Disease Priority Review Voucher and the potential value thereof; the estimated size of the neuroblastoma market opportunity and the potential for expansion into cardiovascular and neurodegenerative disease markets; the Company’s studio model and its ability to identify, launch and build life sciences platforms through EZRA International Group; and the expected long-term value creation from LifeSci Global’s portfolio.
These forward-looking statements are based on management’s current expectations, assumptions and beliefs as of the date of this press release and are subject to known and unknown risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, without limitation: the risk that LifeSci Global does not successfully identify, build or grow portfolio companies; the risk that Scott Korman or David Turner are unable to devote sufficient time and attention to LifeSci Global or cease to be associated with the platform; risks related to the development, regulatory review, clinical testing, approval, commercialization and market adoption of Innervate’s product candidates, including the risk that 18F-mFBG does not receive regulatory approval or does not achieve commercial success; the risk that Innervate does not receive a Rare Pediatric Disease Priority Review Voucher or that any such voucher is not awarded or is not monetized for the amounts historically achieved by other holders of such vouchers; the risk that the estimated neuroblastoma, cardiovascular or neurodegenerative market opportunities do not materialize or are smaller than anticipated; the early-stage nature of Innervate’s development program and the substantial capital, time and regulatory requirements associated therewith; risks related to the dual role of Scott Korman as a member of the Company’s Board of Directors and as Chief Executive Officer of Innervate, including potential conflicts of interest; the Company’s ability to source, evaluate and execute additional life sciences investments through LifeSci Global; intellectual property, clinical, manufacturing, regulatory and data protection risks specific to the radiopharmaceutical and life sciences industries; the Company’s ability to access capital on acceptable terms or at all; and general economic, market and industry conditions.
Such risks and uncertainties also include geopolitical risks, including the ongoing conflict involving Israel and Iran, which may result in regional instability, military activity, cyberattacks, disruptions to critical infrastructure, supply chains or communications networks, or workforce disruptions, any of which could materially adversely affect the Company’s investments, partners or operations, including Innervate’s development activities.
Actual results may differ materially from those expressed or implied by these forward-looking statements. Additional information regarding factors that may cause actual results to differ materially is included under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and in the Company’s subsequent periodic reports and other filings with the Securities and Exchange Commission. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Transaction Expands EZRA International Group’s Biotech Division, LifeSci Global, Into Late-Stage Radiopharmaceutical Imaging
Initial Neuroblastoma Opportunity of Approximately $250 Million, with Additional Potential Billion-Dollar Expansion Markets and Priority Review Voucher Upside
LAKEWOOD, N.J., May 04, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: EZRA) (“we,” “us,” “our,” the “Company” or “Reliance”) today announced that LifeSci Global Group LLC (“LifeSci Global”), the biotech arm of EZRA International Group, has completed a strategic investment in Innervate Radiopharmaceuticals, a developer of positron emission tomography (PET) imaging and therapeutic radiopharmaceuticals focused initially on neuroblastoma and broader future applications in cardiovascular and neurodegenerative disease. This investment reflects an initial capital deployment within a broader strategy to build exposure to high-growth healthcare platforms through disciplined, staged allocation over time.
The transaction gives Reliance entry into a late-stage radiopharmaceutical platform targeting a serious unmet need in pediatric oncology, with additional expansion opportunities in cardiovascular and neurodegenerative disease and the potential for a valuable Priority Review Voucher pathway. Reliance believes the investment represents a compelling opportunity to participate in a differentiated healthcare platform with meaningful near-term upside and substantially larger long-term expansion potential.
As part of the transaction, LifeSci Global is set to acquire 421,053 shares of Innervate Radiopharmaceuticals at $4.75 per share, for a total investment of approximately $2.0 million of which $500,000 was funded at closing. LifeSci Global also holds the unilateral right to accelerate funding.
Innervate’s lead asset, 18F-mFBG, is being developed as a next-generation PET imaging agent for neuroblastoma, a rare and serious pediatric cancer arising from neural crest cells, most commonly in young children. Compared with the current standard of care, 123I-mIBG SPECT imaging, Innervate’s 18F-mFBG PET imaging agent is designed to provide higher-resolution images, faster scan times and improved lesion identification, with the potential to enhance diagnostic confidence, support better-informed patient management and improve the overall patient experience. Innervate’s neuroblastoma program has involved leading institutions in pediatric oncology and nuclear imaging, including Memorial Sloan Kettering Cancer Center and the NANT network. Reliance believes this supports the platform’s strategic significance and clinical relevance.
“We believe this is exactly the type of transformative opportunity EZRA International Group was built to pursue,” said Ezra Beyman, Chairman and Chief Executive Officer of Reliance Global Group. “Innervate represents what we view as a compelling entry into one of the fastest growing and most strategically active segments in healthcare. It combines a differentiated late-stage oncology opportunity, a potentially significant Priority Review Voucher pathway, and what we believe may be a highly expandable platform with applications that extend well beyond the initial indication.”
Mr. Beyman continued, “For Reliance shareholders, we believe this transaction creates exposure to a differentiated late-stage healthcare platform with meaningful near-term upside and substantially larger long-term expansion potential. Neuroblastoma alone represents a meaningful initial opportunity, but what makes this especially compelling is the broader platform potential in cardiovascular and neurodegenerative disease markets that management believes could each exceed $1 billion. We believe this investment reflects the continued execution of our strategy to build long-term shareholder value through targeted ownership in high-upside technology and innovation-driven businesses.” This approach reflects the Company’s broader strategy of identifying differentiated platforms early and building exposure through disciplined capital allocation over time.
Innervate’s 18F-mFBG is intended to help identify areas in the body where cancer may be present by targeting the norepinephrine transporter (NET). Compared with the current standard of care, 123I-mIBG SPECT imaging, PET-based imaging has the potential to offer higher resolution, faster scan times, improved lesion detection, dramatically improved patient experience and greater diagnostic reliability.
Reliance believes Innervate offers a rare combination of a meaningful near-term oncology opportunity and substantially larger follow-on expansion paths. The neuroblastoma market alone represents an estimated annual global revenue opportunity of approximately $250 million, while future cardiovascular and neurodegenerative applications may each address markets exceeding $1 billion. More broadly, PET imaging and radiopharmaceuticals are among the fastest-growing segments in radiology, with annual U.S. sales exceeding $2 billion and global sales exceeding $5 billion, supported by growing clinical adoption, meaningful commercial demand, and robust M&A and strategic activity across the sector. There can be no assurance that Innervate’s products will receive regulatory approval or achieve commercial success, or that any of the market opportunities described herein will be realized. The investment is structured as a staged capital deployment over time, designed to provide continued exposure to the platform as development progresses.
Moshe Fishman, Senior Vice President of Strategic Ventures at Reliance Global Group, said, “We believe Innervate is a particularly attractive fit for EZRA’s biotech division because it combines differentiated science, late-stage positioning and significant strategic optionality. The lead neuroblastoma program addresses an area of urgent medical need, while the broader platform may open the door to substantially larger commercial opportunities over time. In our view, this is not simply an investment in a single asset. It is an investment in a platform that we believe may support multiple future value inflection points.”
Mr. Fishman added, “What stands out to us is the asymmetry of the opportunity. The initial neuroblastoma program appears meaningful on its own, but the additional upside from platform expansion, potential strategic interest and the possibility of a Priority Review Voucher, if ultimately awarded in connection with a future approval, could materially enhance the overall value proposition.”
Innervate has indicated that its lead neuroblastoma program includes a pivotal efficacy and safety study and is advancing toward regulatory submission-related activities. Reliance believes the program’s development timeline may present important future milestone opportunities, including potential clinical and regulatory inflection points. Innervate also anticipates the possibility of receiving a Rare Pediatric Disease Priority Review Voucher in connection with a future approval, which, if awarded, could represent an additional monetizable asset. There can be no assurance that any such voucher will be received or monetized. The Company expects continued progress across the coming quarters, with potential updates on clinical advancement and regulatory pathway activities.
The investment was made through LifeSci Global, a majority-owned subsidiary of the Company. The investment was reviewed and approved by the independent and disinterested members of the Company’s Board of Directors. Interested directors recused themselves from all Board and committee deliberations regarding the transaction.
Scott Korman, a member of the Company’s Board of Directors, serves as the Chief Executive Officer of Innervate and holds an equity interest in LifeSci Global. Ezra Beyman, the Company’s Chairman and Chief Executive Officer, also holds an equity interest in LifeSci Global.
Reliance believes this transaction further validates EZRA International Group’s broader strategy of identifying, acquiring and supporting ownership positions in innovative, high-growth businesses where disciplined capital allocation and active strategic involvement can unlock meaningful long-term shareholder value. With this investment, Reliance expands EZRA International Group into radiopharmaceuticals and advanced medical imaging, as part of its broader strategy of disciplined capital allocation across high-growth technology and life sciences platforms,
About Reliance Global Group, Inc.
Reliance Global Group, Inc. (NASDAQ: EZRA) is an InsurTech pioneer leveraging artificial intelligence (AI) and cloud-based technologies to transform and improve efficiencies in the insurance agency and brokerage industry. The Company’s business-to-business InsurTech platform, RELI Exchange, provides independent insurance agencies with a full suite of business development tools, enabling them to compete effectively with large-scale national insurance agencies while reducing back-office costs and burden. The Company’s business-to-consumer platform, 5minuteinsure.com, uses AI and data mining to provide competitive online insurance quotes within minutes to everyday consumers seeking to purchase auto, home, and life insurance. In addition, the Company operates its own portfolio of select retail brick-and-mortar insurance agencies, which are leaders and pioneers in their respective regions throughout the United States and offer a wide variety of insurance products.
In addition to its insurance and Insurtech operations, Reliance operates EZRA International Group, its strategic growth platform focused on identifying, acquiring, and building majority or controlling stakes in high-growth technology and life sciences companies. EZRA International Group is designed to complement Reliance’s core insurance business by expanding market reach and supporting long-term shareholder value creation through disciplined capital allocation and active ownership.
Forward-looking statements in this press release include, without limitation, statements regarding: the Company’s investment in Innervate Radiopharmaceuticals through LifeSci Global Group LLC; the development, regulatory pathway, clinical progress, commercialization and market potential of Innervate’s product candidates, including 18F-mFBG; the potential for Innervate to receive a Rare Pediatric Disease Priority Review Voucher and the potential value thereof; the estimated size and growth of the neuroblastoma, cardiovascular, neurodegenerative and broader radiopharmaceutical markets; the Company’s strategy of identifying, acquiring and supporting ownership positions in innovative, high-growth businesses through EZRA International Group; and the expected strategic, operational and financial benefits of the Company’s investments.
These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties, many of which are beyond the Company’s control. Such risks and uncertainties include, without limitation: risks related to the development, regulatory review, clinical testing, approval, commercialization and market adoption of Innervate’s product candidates, including the risk that Innervate’s products do not receive regulatory approval or do not achieve commercial success; the risk that Innervate does not receive a Rare Pediatric Disease Priority Review Voucher or that any such voucher is not monetized for the amounts historically achieved by other vouchers; the risk that the estimated market opportunities described herein do not materialize or are smaller than anticipated; integration, execution and scaling challenges associated with supporting an early-stage technology company; the risk that anticipated synergies or strategic benefits are not realized on expected timelines or at all; intellectual property, cybersecurity, regulatory and data protection risks; the Company’s ability to access capital on acceptable terms or at all; and general economic, market and interest rate conditions.
Such risks and uncertainties also include geopolitical risks, including the ongoing and evolving conflict involving Israel and Iran, which may result in regional instability, military activity, cyberattacks, disruptions to critical infrastructure, supply chains or communications networks or workforce disruptions. The extent, duration, and impact of such conditions remain uncertain and could materially adversely affect the Company’s investments and operations.
Actual results may differ materially from those expressed or implied by these forward-looking statements. Additional information regarding factors that may cause actual results to differ materially is included under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, when filed, and in the Company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.
EZRA’s Scale51 Model Continues Advancing Path Toward Majority Control of Post-Quantum Cybersecurity Platform
LAKEWOOD, NJ, April 28, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: EZRA) (“we,” “us,” “our,” the “Company” or “Reliance”) today announced it has increased its ownership in Enquantum Ltd. (“Enquantum”), a developer of next-generation post-quantum cryptographic solutions. Following Enquantum’s completion of defined technical and commercial milestones, the Company funded the next investment tranche, increasing its equity position in Enquantum to approximately 29%. Upon continued execution against the remaining milestone framework, Reliance expects to obtain a 51% fully diluted controlling interest in Enquantum pursuant to the Share Purchase Agreement, dated February 5, 2026, between the Company and Enquantum.
This investment reflects a structured approach to building controlling positions in high-impact technology platforms through measured execution.
“We are actively advancing what we believe to be a clearly defined strategy to build ownership in high-impact technology platforms through disciplined, milestone-based investment,” said Ezra Beyman, Chairman and Chief Executive Officer of Reliance Global Group. “Increasing our position in Enquantum reflects progress across both technical validation and commercial readiness and our conviction in its long-term potential. We are deploying capital in alignment with verified milestone achievement, while maintaining a structured pathway toward a 51% fully diluted controlling interest. We believe this approach allows us to scale our investment responsibly while supporting Enquantum’s continued advancement toward commercialization and broader market adoption.”
Reliance believes Enquantum is positioned within a significant and developing market opportunity as enterprises, infrastructure operators and public-sector organizations prepare for the transition to quantum-resilient security. As demand grows for post-quantum cryptographic solutions that can operate in high-throughput, performance-sensitive environments, the Company believes Enquantum is addressing an important need across regulated financial systems, cloud and AI infrastructure, telecommunications networks, defense environments and other critical digital systems.
Supporting this milestone, Enquantum continued advancing both its core technology platform and its commercial readiness including completion of a defined commercial readiness phase.
During the current funding cycle, the company successfully completed a defined commercial readiness phase, defined buyer-oriented latency performance targets for its alpha version and continued expanding the validation and marketing infrastructure needed to support future customer engagement.
Enquantum established initial latency targets for its alpha version, including 20 to 80 microseconds for Kyber768 key generation and verification and approximately one microsecond for AEAD processing latency. In practical terms, these targets are intended to show that Enquantum is designing for high-throughput infrastructure environments where predictable and measurable latency can be critical to adoption. These performance benchmarks are designed to align with real-world infrastructure requirements, supporting the transition from development to deployment.
Enquantum’s AEAD implementation has also advanced into laboratory testing, with full throughput and latency benchmarking expected to begin shortly. In parallel, the company is developing an in-house post-quantum cryptography test system intended to support ongoing validation while reducing reliance on costly third-party equipment.
At the same time, Enquantum is advancing its commercial efforts, including active engagement with prospective partners and potential design partners across multiple opportunities, while continuing to expand its broader pipeline and prepare for potential infrastructure deployments in priority markets.
“This milestone reflects continued progress in both our technical roadmap and the commercial readiness of our platform,” said Roman Vercetti, Chief Executive Officer of Enquantum. “We have continued refining our architecture, improving the validation environment around the product, and improved efficiency and scalability, and are progressing toward deployment in real-world infrastructure environments. With Reliance’s continued support, we are accelerating development and deepening our engagement with potential partners as demand for quantum-resilient solutions continues to grow.”
Moshe Fishman, Senior Vice President of Strategic Ventures at Reliance Global Group, added, “We are seeing tangible progress at the technology level, particularly around performance validation and deployment readiness, which are important to adoption in infrastructure markets. Increasing our ownership to 29% reflects our confidence in Enquantum’s trajectory and in our continued path toward majority control. We believe the transition to post-quantum encryption represents a significant long-term opportunity within the broader cybersecurity landscape.”
These discussions remain preliminary, and there can be no assurance that they will result in definitive agreements, or that any anticipated partnerships or deployments will occur on acceptable terms or at all.
Reliance views its investment in Enquantum as a key component of EZRA International Group’s broader strategy to identify and scale high-impact technology platforms through disciplined capital deployment, operational support and a defined path to control ownership. Reliance’s approach is focused on building control through execution, with each milestone serving as a validation point toward long-term value creation. This model allows the Company to scale its exposure while managing risk and maintaining alignment with shareholder value creation.
About Reliance Global Group, Inc.
Reliance Global Group, Inc. (NASDAQ: EZRA) is an InsurTech pioneer leveraging artificial intelligence (AI) and cloud-based technologies to transform and improve efficiencies in the insurance agency and brokerage industry. The Company’s business-to-business InsurTech platform, RELI Exchange, provides independent insurance agencies with a full suite of business development tools, enabling them to compete effectively with large-scale national insurance agencies while reducing back-office costs and burden. The Company’s business-to-consumer platform, 5minuteinsure.com, uses AI and data mining to provide competitive online insurance quotes within minutes to everyday consumers seeking to purchase auto, home, and life insurance. In addition, the Company operates its own portfolio of select retail brick-and-mortar insurance agencies, which are leaders and pioneers in their respective regions throughout the United States and offer a wide variety of insurance products.
In addition to its insurance and Insurtech operations, Reliance operates EZRA International Group, its strategic growth platform focused on identifying, acquiring, and building majority or controlling stakes in high-growth technology companies. EZRA International Group is designed to complement Reliance’s core insurance business by expanding market reach and supporting long-term shareholder value creation through disciplined capital allocation and active ownership.
Forward-looking statements in this press release include, without limitation, statements regarding: the Company’s expected pathway to increase its ownership in Enquantum Ltd. (“Enquantum”) to a 51% fully diluted controlling interest pursuant to the Share Purchase Agreement, dated February 5, 2026, between the Company and Enquantum (the “Share Purchase Agreement”); the timing, funding and completion of future milestone-based tranche investments, including the Company’s ability to exercise acceleration rights; the Company’s anticipated ability to obtain additional governance rights, including board representation, upon achievement of specified milestones; the development, performance, scalability, validation and commercialization of Enquantum’s post-quantum cryptographic technology, including Enquantum’s alpha version, its AEAD implementation, its in-house post-quantum cryptography test system, and Enquantum’s ability to meet or achieve its stated latency performance targets, including targets of 20 to 80 microseconds for Kyber768 key generation and verification and approximately one microsecond for AEAD processing latency; Enquantum’s completion of defined technical and commercial milestones, including the commercial readiness phase referenced herein; the preliminary nature of Enquantum’s discussions with prospective partners and potential design partners, and whether any such discussions will result in definitive agreements on acceptable terms or at all; the timing and occurrence of any planned or potential infrastructure deployments by Enquantum in priority markets; the anticipated demand for, and timing of, migration to quantum-resilient encryption standards across regulated financial systems, cloud and AI infrastructure, telecommunications networks, defense environments and other critical digital systems; the size, growth and evolution of the post-quantum cybersecurity market; the Company’s ability to integrate Enquantum within EZRA International Group and execute its Scale51 model; and the expected strategic, operational and financial benefits of the investment.
These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties, many of which are beyond the Company’s control. Such risks and uncertainties include, without limitation: the risk that milestone conditions under the Share Purchase Agreement are not achieved or are delayed; the risk that the Company is unable to fund future tranche investments on anticipated terms or timelines; the risk that the Company does not ultimately obtain majority ownership or governance control of Enquantum; risks related to the development, validation, performance, latency benchmarking, regulatory acceptance, commercialization or market adoption of Enquantum’s post-quantum cryptographic technology, including the risk that Enquantum’s alpha version or AEAD implementation does not achieve targeted performance, throughput or latency benchmarks, or does not do so on anticipated timelines; the risk that Enquantum’s preliminary discussions with prospective partners or design partners do not result in definitive agreements on acceptable terms, or at all; the risk that any anticipated or planned infrastructure deployments do not occur as expected or are delayed or cancelled; the risk that post-quantum standards adoption or infrastructure migration occurs more slowly or differently than anticipated; integration, execution and scaling challenges associated with supporting an early-stage technology company; the risk that anticipated synergies or strategic benefits are not realized on expected timelines or at all; intellectual property, cybersecurity, regulatory and data protection risks; the Company’s ability to access capital on acceptable terms or at all; and general economic, market and interest rate conditions.
Such risks and uncertainties also include geopolitical risks, including the ongoing and evolving conflict involving Israel and Iran, which may result in regional instability, military activity, cyberattacks, disruptions to critical infrastructure, supply chains or communications networks, workforce disruptions, delays in development, testing or deployment activities, or limitations on Enquantum’s ability to operate in or access certain markets. Recent developments have included an escalation in state-sponsored and retaliatory cyber activity and attacks on infrastructure in the region, which could adversely impact technology companies operating in or connected to the region. The extent, duration, and impact of such conditions remain uncertain and could materially adversely affect Enquantum’s operations and the Company’s investment.
Actual results may differ materially from those expressed or implied by these forward-looking statements. Additional information regarding factors that may cause actual results to differ materially is included under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, when filed, and in the Company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.
Lakewood, New Jersey–(Newsfile Corp. – April 10, 2026) – Reliance Global Group, Inc. (NASDAQ: EZRA) (“we,” “us,” “our,” the “Company” or “Reliance”) today announced that Ezra Beyman, Chairman and Chief Executive Officer, Moshe Fishman, Senior Vice President, Strategic Ventures, and Grant Barra, Senior Vice President of Operations, will be participating in the Centri Capital Conference, which will take place at the premier Nasdaq MarketSite location in New York City (151 West 43rd Street) on Tuesday, April 14, 2026. The one-day event brings together emerging growth companies, institutional investors, family offices, and capital markets professionals for presentations, fireside chats, and one-on-one meetings focused on investment opportunities and long-term growth strategies.
Reliance Global Group will participate in a fireside chat at 2:30 PM Eastern Time and will also be available for one-on-one meetings with investors throughout the day.
The Centri Capital Conference is designed to facilitate meaningful engagement between company executives and the investment community. The invite-only event offers attendees insights into company strategies, financial performance, and growth initiatives across a diverse range of industries. To express interest in attending, please complete the registration form here.
Reliance Global Group, Inc. (NASDAQ: EZRA) is an InsurTech pioneer, leveraging artificial intelligence (AI), and cloud-based technologies, to transform and improve efficiencies in the insurance agency/brokerage industry. The Company’s business-to-business InsurTech platform, RELI Exchange, provides independent insurance agencies with an entire suite of business development tools, enabling them to effectively compete with large-scale national insurance agencies, while reducing back-office cost and burden. The Company’s business-to-consumer platform, 5minuteinsure.com, utilizes AI and data mining, to provide competitive online insurance quotes within minutes to everyday consumers seeking to purchase auto, home, and life insurance. In addition, the Company operates its own portfolio of select retail “brick and mortar” insurance agencies which are leaders and pioneers in their respective regions throughout the United States, offering a wide variety of insurance products.
In addition to its insurance and Insurtech operations, Reliance operates EZRA International Group, its strategic growth platform focused on identifying, acquiring, and building majority or controlling stakes in high-growth technology companies. EZRA International Group is designed to complement Reliance’s core insurance business by expanding market reach and supporting long-term shareholder value creation through disciplined capital allocation and active ownership.
Next phase of RELI Exchange is designed to expand recruiting capacity, improve execution and build on the platform’s strong operating momentum
LAKEWOOD, NJ, March 25, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: EZRA) (“we,” “us,” “our,” the “Company” or “Reliance”) today announced the launch of RELI Exchange 2.0, the next phase of its InsurTech platform for independent insurance agencies, designed to expand recruiting capacity, improve execution and position the platform for faster, more efficient growth.
In February 2026, Reliance reported that health insurance policies written through RELI Exchange during the 2025 open enrollment period increased 72% year over year, Personal Lines Property and Casualty written premium increased 36% year over year, and the broker network expanded from approximately 65 to approximately 300 agency partners since 2022. RELI Exchange 2.0 is designed to build on that momentum by making the platform faster, more disciplined, and more effective as a growth engine.
The upgrade brings recruiting activity into a centralized operating environment with defined pipeline stages, integrated task management, and full communication tracking. Reliance believes these enhancements can support faster follow-up, better prioritization, stronger recruiter productivity, greater outreach capacity, and stronger forecasting, while enabling the Company to manage higher recruiting volumes with greater speed and efficiency as the platform continues to expand.
“RELI Exchange 2.0 is about making an already scalable and successful platform even more effective as a growth engine,” said Ezra Beyman, Chairman and Chief Executive Officer of Reliance Global Group. “RELI Exchange has already delivered strong operating momentum, and we believe this upgrade gives us the infrastructure to move faster, execute more efficiently and support growth across our agency partner network.”
Mr. Beyman continued, “By improving visibility, workflow discipline and recruiting capacity, RELI Exchange 2.0 is designed to help us scale the platform with greater speed and efficiency. We expect this upgrade to increase recruiter activity levels, including more consistent follow-up and a higher number of agent engagements per recruiter, while enabling the team to manage greater volume without additional headcount. Just as important, it creates a foundation for future automation and more intelligent, data-driven capabilities that we believe can further enhance execution over time.”
About Reliance Global Group, Inc.
Reliance Global Group, Inc. (NASDAQ: EZRA) is an InsurTech pioneer, leveraging artificial intelligence (AI), and cloud-based technologies, to transform and improve efficiencies in the insurance agency/brokerage industry. The Company’s business-to-business InsurTech platform, RELI Exchange, provides independent insurance agencies with an entire suite of business development tools, enabling them to effectively compete with large-scale national insurance agencies, while reducing back-office cost and burden. The Company’s business-to-consumer platform, 5minuteinsure.com, utilizes AI and data mining, to provide competitive online insurance quotes within minutes to everyday consumers seeking to purchase auto, home, and life insurance. In addition, the Company operates its own portfolio of select retail “brick and mortar” insurance agencies which are leaders and pioneers in their respective regions throughout the United States, offering a wide variety of insurance products.
In addition to its insurance and Insurtech operations, Reliance operates EZRA International Group, its strategic growth platform focused on identifying, acquiring, and building majority or controlling stakes in high-growth technology companies. EZRA International Group is designed to complement Reliance’s core insurance business by expanding market reach and supporting long-term shareholder value creation through disciplined capital allocation and active ownership.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identifiable by the use of words or expressions such as “may,” “should,” “could,” “would,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “continue,” “seek,” “potential,” “target,” or similar expressions.
Forward-looking statements in this press release include, without limitation, statements regarding: the expected benefits, capabilities and performance of RELI Exchange 2.0, including its ability to improve recruiting efficiency, increase recruiter productivity, enhance workflow discipline, expand outreach capacity, improve forecasting and support higher recruiting volumes; the Company’s expectations regarding continued growth of its broker network, policy volume and written premium; the ability of RELI Exchange 2.0 to drive faster and more efficient growth and serve as a scalable growth engine; and the Company’s expectations regarding future automation, data-driven capabilities and overall platform development.
These forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, many of which are beyond the Company’s control. Such risks and uncertainties include, without limitation: the risk that RELI Exchange 2.0 does not perform as expected or deliver the anticipated operational or financial benefits; risks associated with the implementation, adoption and scaling of new technology platforms and systems; the Company’s ability to effectively manage increased recruiting activity and platform usage; the risk that increased recruiting activity does not translate into increased revenue or profitability; dependence on independent agency partners and the Company’s ability to attract, retain and support such partners; risks related to data accuracy, system integration, automation and cybersecurity; competitive pressures in the insurance and InsurTech markets; and general business, economic, market, interest rate and geopolitical conditions.
Actual results may differ materially from those expressed or implied by these forward-looking statements. Additional information regarding factors that may cause actual results to differ materially is included under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as amended, and in the Company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.
Milestone-Based Execution Continues Under EZRA’s Scale51 Platform
LAKEWOOD, NJ, March 19, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: EZRA) (“we,” “us,” our,” the “Company” or “Reliance”) today announced that it has funded the next completed milestone in its strategic investment in Enquantum Ltd., a post-quantum cryptography company developing quantum-resilient encryption technology for high-performance environments.
We believe this milestone marks a significant step forward in Enquantum’s commercialization strategy under the Scale51 execution plan, highlighted by continued advancement of its core technology and R&D capabilities, positioning the company for upcoming deployment activities. Enquantum is now actively engaging with prospective partners in North America and moving forward with planned implementation in high-value private network environments in Israel, including program in the southern region of Israel.
With completion of this milestone, Reliance funded the next investment tranche, increasing its ownership position in Enquantum by an additional 4% to approximately 12% on a fully diluted basis and securing an additional board seat under the investment agreement. The agreement details structured, milestone-based tranche investments designed to increase Reliance’s ownership position to a 51% fully diluted controlling interest when all milestones are completed or upon our acceleration at our discretion.
“We believe this milestone reflects the disciplined execution model we outlined from the beginning, where capital is deployed as defined operating objectives are achieved,” said Ezra Beyman, Chairman and Chief Executive Officer of Reliance Global Group. “We expect Enquantum to continue to advance against that framework. This funding increases both our ownership position and our governance role as we continue to execute on EZRA’s Scale51 acquisition platform. We believe this structured approach supports long-term value creation while advancing our path toward a majority position.”
Enquantum represents the first active platform investment under EZRA International Group’s Scale51 model, which is designed to identify high-impact technology opportunities, structure disciplined pathways to majority control, and provide active operational support as companies advance toward broader commercialization and scale.
Google’s recent initiative to develop quantum-safe HTTPS infrastructure underscores the urgency of transitioning the internet’s core security layers to post-quantum standards. The introduction of Merkle Tree Certificates highlights the real-world challenges of deploying quantum-resistant cryptography at scale, particularly around efficiency, bandwidth, and system architecture, reinforcing that quantum resilience is now an active, near-term transformation led by major technology platforms. As foundational protocols like TLS continue to evolve, we believe the need for adaptable and scalable cryptographic solutions becomes increasingly critical across global digital infrastructure.
Enquantum is focused on addressing this shift by developing technologies designed to support the next generation of quantum-resilient security frameworks. Specifically, Enquantum is developing hardware-accelerated, NIST-aligned post-quantum cryptographic solutions engineered for high-throughput, performance-sensitive environments. The Company believes performance validation is an important requirement for adoption across infrastructure markets where encryption must be strengthened without impairing throughput or latency.
“With global cybersecurity spending expected to surpass $300 billion annually by 2029, the urgency around digital risk management continues to intensify.” said Moshe Fishman, Senior Vice President of Strategic Ventures. “We believe the transition to quantum-resilient encryption represents one of the most significant structural shifts in cybersecurity, given encryption’s foundational role across modern digital infrastructure. Enquantum is positioned to play a key role in enabling this transition.”
Reliance views Enquantum as strategically positioned within a broader transition toward quantum-resilient security across regulated financial systems, cloud and AI infrastructure, telecommunications networks, and public-sector environments. Through Scale51 and EZRA International Group, Reliance intends to support Enquantum not only with capital, but also with operational guidance, strategic relationships, and commercialization support as it advances in the market.
About Reliance Global Group, Inc.
Reliance Global Group, Inc. (NASDAQ: EZRA) is an InsurTech pioneer, leveraging artificial intelligence (AI), and cloud-based technologies, to transform and improve efficiencies in the insurance agency/brokerage industry. The Company’s business-to-business InsurTech platform, RELI Exchange, provides independent insurance agencies an entire suite of business development tools, enabling them to effectively compete with large-scale national insurance agencies, whilst reducing back-office cost and burden. The Company’s business-to-consumer platform, 5minuteinsure.com, utilizes AI and data mining, to provide competitive online insurance quotes within minutes to everyday consumers seeking to purchase auto, home, and life insurance. In addition, the Company operates its own portfolio of select retail “brick and mortar” insurance agencies which are leaders and pioneers in their respective regions throughout the United States, offering a wide variety of insurance products.
In addition to its insurance and Insurtech operations, Reliance operates EZRA International Group, its strategic growth platform focused on identifying, acquiring, and building majority or controlling stakes in high-growth technology companies. EZRA International Group is designed to complement Reliance’s core insurance business by expanding market reach and supporting long-term shareholder value creation through disciplined capital allocation and active ownership.
Forward-looking statements in this press release include, without limitation, statements regarding: the Company’s expected pathway to increase its ownership in Enquantum Ltd. (“Enquantum”) to a 51% fully diluted controlling interest pursuant to the definitive agreement; the timing, funding and completion of future milestone-based tranche investments, including the Company’s ability to exercise acceleration rights; the Company’s anticipated ability to obtain additional governance rights, including board representation, upon achievement of specified milestones; the development, performance, scalability, validation and commercialization of Enquantum’s post-quantum cryptographic technology; Enquantum’s engagement with prospective partners and planned deployments in Israel and other markets; the anticipated demand for, and timing of, migration to quantum-resilient encryption standards; the size, growth and evolution of the post-quantum cybersecurity market; the Company’s ability to integrate Enquantum within EZRA International Group and execute its Scale51 operating model; and the expected strategic, operational and financial benefits of the investment.
These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties, many of which are beyond the Company’s control. Such risks and uncertainties include, without limitation: the risk that milestone conditions are not achieved or are delayed; the risk that the Company is unable to fund future tranche investments on anticipated terms or timelines; the risk that the Company does not ultimately obtain majority ownership or governance control; risks related to the development, validation, performance, regulatory acceptance, commercialization or market adoption of Enquantum’s technology; the risk that anticipated partner engagements or planned deployments, including in Israel, do not occur as expected or are delayed or cancelled; the risk that post-quantum standards adoption or infrastructure migration occurs more slowly or differently than anticipated; integration, execution and scaling challenges associated with supporting an early-stage technology company; the risk that anticipated synergies or strategic benefits are not realized on expected timelines or at all; intellectual property, cybersecurity, regulatory and data protection risks; the Company’s ability to access capital on acceptable terms or at all; and general economic, market and interest rate conditions.
Such risks and uncertainties also include geopolitical risks, including the ongoing and evolving conflict involving Israel and Iran, which may result in regional instability, military activity, cyberattacks, disruptions to critical infrastructure, supply chains or communications networks, workforce disruptions, delays in development, testing or deployment activities, or limitations on Enquantum’s ability to operate in or access certain markets. Recent developments have included an escalation in state-sponsored and retaliatory cyber activity and attacks on infrastructure in the region, which could adversely impact technology companies operating in or connected to the region. The extent, duration and impact of such conditions remain uncertain and could materially adversely affect Enquantum’s operations and the Company’s investment.
Actual results may differ materially from those expressed or implied by these forward-looking statements. Additional information regarding factors that may cause actual results to differ materially is included under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as amended, and in the Company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.
Closing of Purchase Agreement in Post Quantum Cybersecurity Company Mark First Step in the Scale51 Technology Expansion Strategy
Company to Host Conference Call Today at 4:30 PM Eastern Time
LAKEWOOD, N.J., March 10, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: EZRA) (“we,” “us,” “our,” the “Company” or “Reliance”) today reported financial results for the year ended December 31, 2025, and provided a strategic update on the Company’s Scale51 initiative, including the launch of EZRA International Group and the closing of the purchase agreement with Enquantum Ltd., a post quantum cybersecurity company. Scale51 represents the Company’s structured framework for expanding into technology driven sectors through disciplined investments and strategic partnerships, while continuing to operate and develop its established insurance platform.
Key Highlights
EZRA International Group launched Scale51, a strategic technology-focused platform designed to identify and scale high growth companies innovative across cybersecurity, artificial intelligence, fintech, and digital health.
Completed a first investment in Enquantum Ltd., establishing a pathway toward majority control of a post-quantum cybersecurity platform developing next-generation encryption technology.
Signed a non-binding Term Sheet to acquire a majority stake in Scentech Medical, an AI-based diagnostics company, developing non-invasive breath-based disease detection technology. The contemplated acquisition, if closed would position the Company in the rapidly evolving field of AI-driven medical diagnostics.
Strengthened the balance sheet through strategic divestitures, including the sale of Fortman Insurance Services and other non-core assets, enabling significant debt reduction and improved financial flexibility.
“2025 was a transition year focused on enhancing the balance sheet, streamlining operations, and positioning Reliance to execute its Scale51 technology growth strategy,” said Ezra Beyman, Chairman and Chief Executive Officer of Reliance Global Group. “We strengthened our insurance and InsurTech operations, generating more than $12 million in commission income, reflecting the strategic divestiture of non-core operations during the year, allowing the Company to focus capital on higher growth opportunities. The increase in salaries and wages was primarily driven by non-cash, share-based compensation, aligning management incentives with long-term shareholder value creation. Overall, we reduced net loss year over year and improved our balance sheet through strategic divestitures and debt reduction.”
Mr. Beyman continued, “During the year we launched EZRA International Group and our Scale51 operating model, establishing an operational platform to begin building a portfolio of technology-driven businesses in high-growth sectors. Our investment in Enquantum, which establishes a pathway toward majority control of a post-quantum cybersecurity platform, and our non-binding term sheet we entered into to acquire a majority stake in Scentech Medical, an AI based diagnostics company, represent early examples of the innovative technology companies we intend to help scale. Our insurance and InsurTech operations continue to provide a stable operating foundation while the Company expands into technology sectors through the Scale51 growth strategy.”
Strategic Update
During 2025, Reliance advanced its strategy to build a diversified operating platform combining its established insurance and InsurTech operations with technology-driven growth initiatives. A key milestone was the launch of EZRA International Group, a division focused on identifying and scaling innovative technology companies. Supporting this initiative is the Company’s Scale51 operating model, designed to work alongside management teams to accelerate commercial growth and expand technologies into global markets.
As part of this strategy, Reliance completed an investment in Enquantum Ltd., a cybersecurity company developing post-quantum encryption technologies designed to protect digital infrastructure from emerging threats associated with advances in quantum computing. The transaction establishes a pathway for Reliance to obtain majority control of the Enquantum platform as the business continues to scale.
The Company has also entered into an non-binding term sheet to acquire a majority stake in Scentech Medical, an AI-based diagnostics company developing non-invasive breath-analysis product candidate to detect disease-associated molecular signatures.
Reflecting its evolving strategic direction, the Company transitioned its Nasdaq ticker symbol from RELI to EZRA during the year.
Reliance’s insurance and InsurTech operations continue to provide a stable operating foundation, generating more than $12 million in commission income during 2025. Management remains focused on enhancing operational efficiency within its insurance and InsurTech operations while pursuing targeted technology investments through EZRA International Group.
During 2025, Reliance also simplified its operating structure and strengthened its balance sheet through several strategic actions. The Company completed the sale of Fortman Insurance Services and divested its remaining Employee Benefits Solutions and U.S. Benefits Alliance businesses, generating capital used to reduce long-term debt and improve financial flexibility.
Management intends to continue identifying opportunities to expand its technology platform through EZRA International Group while maintaining disciplined capital allocation.
2025 Financial Highlights
The following summarizes select financial results for the year ended December 31, 2025:
Strategic transition and portfolio realignment: During 2025, the Company executed a portfolio realignment through the sale of Fortman Insurance Services, Employee Benefits Solutions, and U.S. Benefits Alliance. Proceeds from these transactions were used to reduce debt, strengthen the balance sheet, and simplify operations as Reliance repositioned the business to advance its Scale51 technology growth strategy. The Company’s insurance brokerage and InsurTech platforms continue to provide a stable operating foundation supporting this expansion.
Unrestricted cash increased by approximately $0.9 million, or 250%, to approximately $1.3 million as of December 31, 2025, compared with approximately $0.4 million as of December 31, 2024.
Working capital improved by approximately $1.5 million, or 351%, to approximately $1.9 million as of December 31, 2025, and stockholders’ equity increased by approximately $3.4 million, or 114%, to approximately $6.4 million, compared with December 31, 2024.
Commission income was $12.4 million for the year ended December 31, 2025, compared with $14.1 million for the year ended December 31, 2024, representing a decrease of $1.6 million, or 12%. The decrease was primarily attributable to the Company’s portfolio realignment during 2025, including the divestiture of the Fortman Insurance Services, Employee Benefits Solutions, and U.S. Benefits Alliance businesses.
Commission expense was $4.6 million in 2025, compared with $4.2 million in 2024, representing an increase of $0.4 million, or 10%. The increase primarily reflects higher commissions associated with increased sales activity in certain of the Company’s operations, as well as general market-driven increases in commission rates across the insurance sector.
Salaries and wages totaled $10.3 million in 2025, compared with $7.2 million in 2024, representing an increase of $3.1 million, or 43%. The increase was primarily attributable to non-cash share-based compensation, partially offset by the elimination of salaries associated with Fortman Insurance Services following its divestiture.
General and administrative expenses were $4.9 million in 2025, compared with $4.2 million in 2024, representing an increase of $0.7 million, or 16%. The increase was primarily driven by non-cash equity awards to directors and service providers, partially offset by operational efficiencies associated with the Company’s OneFirm initiative.
Net lossimproved to $7.0 million in 2025, compared with $9.1 million in 2024, representing an improvement of $2.1 million. The improvement was primarily attributable to the gain recognized on the sale of certain businesses during the year, as well as the absence of asset impairment charges recorded in the prior year.
Adjusted EBITDA (“AEBITDA”), a non-GAAP financial measure, was ($1.6 million) in 2025, compared with ($0.3 million) in 2024. The change was primarily driven by lower revenue following the Company’s portfolio realignment transactions during 2025, as well as higher operating costs and higher commission expense associated with increased sales activity within certain of the Company’s remaining operations.
Conference Call
Reliance Global Group will host a conference call Tuesday, March 10, 2026, at 4:30 PM Eastern Time to discuss financial results and provide a business update.
A webcast replay will be available on the investor relations section of the Company’s website through March 10, 2027. A telephone replay will be available approximately one hour following the call through March 24, 2026, and can be accessed by dialing +1 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering access code 53733.
About Reliance Global Group, Inc.
Reliance Global Group, Inc. (NASDAQ: EZRA) is an InsurTech pioneer, leveraging artificial intelligence (AI), and cloud-based technologies, to transform and improve efficiencies in the insurance agency/brokerage industry. The Company’s business-to-business InsurTech platform, RELI Exchange, provides independent insurance agencies an entire suite of business development tools, enabling them to effectively compete with large-scale national insurance agencies, whilst reducing back-office cost and burden. The Company’s business-to-consumer platform, 5minuteinsure.com, utilizes AI and data mining, to provide competitive online insurance quotes within minutes to everyday consumers seeking to purchase auto, home, and life insurance. In addition, the Company operates its own portfolio of select retail “brick and mortar” insurance agencies which are leaders and pioneers in their respective regions throughout the United States, offering a wide variety of insurance products.
In addition to its insurance and InsurTech operations, Reliance operates EZRA International Group, its strategic growth platform focused on identifying, acquiring, and building majority or controlling stakes in high-growth technology companies. EZRA International Group is designed to complement Reliance’s core insurance business by expanding market reach and supporting long-term shareholder value creation through disciplined capital allocation and active ownership.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identifiable by the use of words or expressions such as “may,” “should,” “could,” “would,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “continue,” “seek,” “potential,” “target,” or similar expressions.
Forward-looking statements in this press release include, without limitation, statements regarding: the Company’s strategy to expand into technology-driven sectors through its Scale51 initiative and EZRA International Group platform; the Company’s ability to identify, acquire, invest in and scale innovative technology companies; the potential acquisition of a majority stake in Scentech Medical pursuant to the non-binding term sheet and the timing or likelihood of entering into definitive agreements or completing such transaction; the Company’s investment in Enquantum Ltd. and the anticipated development, commercialization and market adoption of its post-quantum cybersecurity technologies; the Company’s ability to integrate or support technology businesses within its operating platform; anticipated strategic, operational and financial benefits of these initiatives; the Company’s ability to continue strengthening its balance sheet and redeploy capital following the sale of non-core insurance operations; and the Company’s broader business strategy, capital allocation priorities and growth outlook.
These forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, many of which are beyond the Company’s control. Such risks and uncertainties include, without limitation: the risk that the contemplated transaction with Scentech Medical is not completed or is completed on different terms than currently anticipated; risks associated with early-stage technology investments, including the development, commercialization and adoption of new technologies; the Company’s ability to successfully execute its Scale51 strategy and integrate or support new technology investments; the possibility that anticipated strategic or financial benefits from these initiatives may not be realized within expected timeframes or at all; the Company’s ability to access capital and maintain sufficient liquidity to support its strategic initiatives; risks associated with operating in emerging technology sectors including cybersecurity, artificial intelligence and digital health; and general business, economic, market, interest rate and geopolitical conditions.
Actual results may differ materially from those expressed or implied by these forward-looking statements. Additional information regarding factors that may cause actual results to differ materially is included under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as amended, and in the Company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.
INFORMATION REGARDING A NON-GAAP FINANCIAL MEASURE
The Company believes certain financial measures which meet the definition of non-GAAP financial measures, as defined in Regulation G of the SEC rules, provide important supplemental information. Namely our key financial performance metric Adjusted EBITDA (“AEBITDA”) is a non-GAAP financial measure that is not in accordance with, or an alternative to, measures prepared in accordance with GAAP. “AEBITDA” is defined as earnings before interest, taxes, depreciation, and amortization (EBITDA) with additional adjustments as further outlined below, to result in Adjusted EBITDA (“AEBITDA”). The Company considers AEBITDA an important financial metric because it provides a meaningful financial measure of the quality of the Company’s operational, cash impacted and recurring earnings and operating performance across reporting periods. Other companies may calculate Adjusted EBITDA differently than we do, which might limit its usefulness as a comparative measure to other companies in the industry. AEBITDA is used by management in addition to and in conjunction (and not as a substitute) with the results presented in accordance with GAAP. Management uses AEBITDA to evaluate the Company’s operational performance, including earnings across reporting periods and the merits for implementing cost-cutting measures. We have presented AEBITDA solely as supplemental disclosure because we believe it allows for a more complete analysis of results of operations and assists investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Consistent with Regulation G, a description of such information is provided below herein and tabular reconciliations of this supplemental non-GAAP financial information to our most comparable GAAP information are contained in this Annual Report on Form 10-K under “Results of Operations”.
We exclude the following items, and the following items define our non-GAAP financial measure AEBITDA:
Interest and related party interest expense: Unrelated to core Company operations and excluded to provide more meaningful supplemental information regarding the Company’s core operational performance. Depreciation and amortization: Non-cash charge, excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
Goodwill and/or asset impairment: Non-cash charge, excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
Equity-based compensation: Non-cash compensation provided to employees, directors and third parties, excluded to provide more meaningful supplemental information regarding the Company’s core cash impacted operational performance.
Change in estimated acquisition earn-out payables: An Earn-out liability is a liability to the seller upon an acquisition which is contingent on future earnings. These liabilities are valued at each reporting period and the changes are reported as either a gain or loss in the change in estimated acquisition earn-out payables account in the consolidated statements of operations. The gain or loss is non-cash, can be highly volatile and overall is not deemed relevant to ongoing operations, thus, it’s excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
Recognition and change in fair value of warrant liabilities: This account includes changes to derivative warrant liabilities which are valued at each reporting period and could result in either a gain or loss. The period changes do not impact cash, can be highly volatile, and are unrelated to ongoing operations, and thus are excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
Other (income) expense, net: This account includes non-routine and/or non-core operating income or expenses and other individually de minimis items and these amounts are excluded as unrelated to core operations of the company.
Gain on sale: This account includes gains on sale from certain agency divestitures that occurred in the period which are unrelated to primary Company operations and are excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
Transactional costs: This includes expenses related to mergers, acquisitions, financings and refinancings, and amendments or modification to indebtedness. These costs are unrelated to primary Company operations and are excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
Non-standard costs: This account includes non-standard non-operational items, related to costs incurred for a legal suit the Company has filed against one of the third parties involved in the previously disclosed discontinued operations and is excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
Unrealized and realized gains (losses) on digital assets, net: This account includes unrealized and realized gains and losses from digital assets and is thus excluded to provide more meaningful supplemental information regarding the Company’s core operational performance.
The following table provides a reconciliation from net loss to AEBITDA for the periods ended December 31, 2025 and 2024, respectively:
December 31, 2025
December 31, 2024
Net income (loss)
$
(6,987,756
)
$
(9,071,584
)
Adjustments:
Interest and related party interest expense
1,043,274
1,583,610
Depreciation and amortization
1,331,846
1,786,068
Asset impairment
–
3,922,110
Goodwill Impairment
–
–
Equity based compensation employees, directors and third parties
5,708,028
858,108
Change in estimated acquisition earn-out payables
–
47,761
Other (income) expense, net
–
(51,345
)
Gain on sale
(3,182,917
)
–
Transactional costs
453,686
636,494
Non-standard costs
(22,294
)
123,554
Unrealized and realized gains (losses) on digital assets, net
59,505
–
Recognition and change in fair value of warrant liabilities
LAKEWOOD, N.J., March 06, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (NASDAQ: EZRA) (“Reliance” or the “Company”), announced today that it will host a conference call Tuesday, March 10, 2026, at 4:30 PM Eastern Time to discuss financial results for the fourth quarter 2025 and provide a business update.
A webcast replay will be available on the investor relations section of the Company’s website at https://relianceglobalgroup.com/events-and-presentations/ through March 10, 2027. A telephone replay of the call will be available approximately one hour following the call, through March 24, 2026, and can be accessed by dialing +1 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering access code 53733.
About Reliance Global Group, Inc.
Reliance Global Group, Inc. (NASDAQ: EZRA) is an InsurTech pioneer, leveraging artificial intelligence (AI), and cloud-based technologies, to transform and improve efficiencies in the insurance agency/brokerage industry. The Company’s business-to-business InsurTech platform, RELI Exchange, provides independent insurance agencies an entire suite of business development tools, enabling them to effectively compete with large-scale national insurance agencies, whilst reducing back-office cost and burden. The Company’s business-to-consumer platform, 5minuteinsure.com, utilizes AI and data mining, to provide competitive online insurance quotes within minutes to everyday consumers seeking to purchase auto, home, and life insurance. In addition, the Company operates its own portfolio of select retail “brick and mortar” insurance agencies which are leaders and pioneers in their respective regions throughout the United States, offering a wide variety of insurance products.
In addition to its insurance and Insurtech operations, Reliance operates EZRA International Group, its strategic growth platform focused on identifying, acquiring, and building majority or controlling stakes in high-growth technology companies. EZRA International Group is designed to complement Reliance’s core insurance business by expanding market reach and supporting long-term shareholder value creation through disciplined capital allocation and active ownership.
Post-Quantum Encryption Transition Expected to Drive a Multi-Year Global Cybersecurity Upgrade Cycle
LAKEWOOD, NJ, Feb. 23, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: EZRA) (“we,” “us,” our,” the “Company” or “Reliance”) today announced the completion of its strategic acquisition of Enquantum Ltd., a post-quantum cryptography company developing quantum-resilient encryption technology. The transaction marks the first active platform acquisition executed under EZRA’s Scale51 operating model and establishes a defined pathway toward majority control as the Company moves to build Enquantum into a core operating platform within EZRA International Group. Quantum computing advancement is accelerating globally, intensifying concern that widely deployed encryption standards such as Rivest-Shamir-Adleman (RSA) and Elliptic Curve Cryptography (ECC) – which secure financial systems, hyperscale cloud infrastructure, telecommunications backbones, AI platforms, government systems, and other critical infrastructure – may become vulnerable to quantum-enabled attacks. Security agencies and industry experts have warned of “harvest now, decrypt later” strategies, in which encrypted data is captured today with the expectation it may be decrypted once sufficiently advanced quantum systems become available.
In response, global standards bodies including the U.S. National Institute of Standards and Technology (NIST) are advancing post-quantum cryptographic standards in preparation for what many expect to be a multi-year infrastructure upgrade cycle across public and private networks.
Global cybersecurity spending is projected to exceed $300 billion annually by 2029, which we believe reflects the growing scale and urgency of digital risk management. We believe that the transition to quantum-resilient encryption may represent one of the most consequential structural shifts within that broader cybersecurity landscape, as encryption underpins virtually all modern digital infrastructure.
Post-quantum security is moving from research into infrastructure planning. Cryptographic migrations require extended integration timelines involving hardware implementation, network redesign, compliance validation, and interoperability testing. Organizations responsible for protecting sensitive data and critical systems are increasingly evaluating post-quantum frameworks well before full-scale quantum capability emerges.
Enquantum is developing hardware-accelerated, NIST-aligned post-quantum cryptographic solutions engineered for high-throughput, performance-sensitive environments. Enquantum’s architecture is designed to operate at terabit scale without degrading latency – a key requirement for financial institutions, telecommunications carriers, cloud providers, data centers, and government networks. In 2025, Enquantum was granted a patent covering FPGA-based encrypted communications utilizing quantum-resistant techniques, reinforcing its intellectual property position and technical differentiation.
“This transaction advances our strategy to acquire majority control of a company in an increasingly important sector as the industry transitions to post-quantum standards,” said Ezra Beyman, Chairman and Chief Executive Officer of Reliance Global Group. “We structured a milestone-driven acquisition pathway designed to culminate in majority control ownership, and today we executed Phase I. We believe, post-quantum encryption is not optional over the long term – it is a structural shift in how critical systems will be secured. We intend to build Enquantum into a scaled operating business under our control.”
Moshe Fishman, Senior Vice President of Strategic Ventures, added, “Infrastructure-level encryption changes take years to deploy. Organizations cannot afford to wait until quantum systems are fully mature before preparing. Enquantum’s hardware-based approach is designed for environments where security upgrades must be implemented without sacrificing throughput or operational performance. Our staged acquisition framework aligns capital deployment with measurable execution milestones as we advance toward majority ownership. Our decision to acquire Enquantum reflects our strategy to secure ownership in foundational cybersecurity infrastructure while actively supporting commercialization. Beyond capital, Reliance brings operational scaling experience, strategic partnerships, and market-access capabilities that we believe can accelerate Enquantum’s path into the North American market, including government and advanced enterprise environments with our business partners, as demand for quantum-resilient encryption grows.”
Roman Vercetti, CEO of Enquantum Ltd. commented, “Enquantum is very excited to partner with Reliance Global Group to deliver market-leading Post Quantum innovative solutions for the future of networking and security. Reliance’s EZRA International Group shares our vision towards a safer, faster and smarter connected world.”
Under the terms of the definitive agreement, Reliance acquired an initial equity position in Enquantum through the conversion of a previously issued secured bridge note and an additional cash investment as the first milestone payment. The agreement provides for structured, milestone-based tranche investments designed to increase Reliance’s ownership position over time to a 51% fully diluted controlling interest, subject to the achievement of specified operational and commercialization milestones and satisfaction of customary conditions. Reliance expects to obtain majority governance rights upon the achievement and funding of specified milestones.
The Enquantum transaction represents the first executed platform investment under the Company’s Scale51 operating model as part of the Company’s EZRA International Group strategy. Scale51 is designed to identify high-impact technology sectors, structure disciplined pathways to majority control, and provide active operational support to scale businesses with long-term value potential.
The transition toward quantum-resilient security is expected to affect regulated financial systems, cloud and AI infrastructure, telecommunications networks, defense environments, and other critical systems that rely on modern cryptographic protection. Through its planned majority ownership strategy, the Company intends to position Enquantum to participate in this migration as adoption expands globally.
About Reliance Global Group, Inc.
Reliance Global Group, Inc. (NASDAQ: EZRA) is an InsurTech pioneer, leveraging artificial intelligence (AI), and cloud-based technologies, to transform and improve efficiencies in the insurance agency/brokerage industry. The Company’s business-to-business InsurTech platform, RELI Exchange, provides independent insurance agencies an entire suite of business development tools, enabling them to effectively compete with large-scale national insurance agencies, whilst reducing back-office cost and burden. The Company’s business-to-consumer platform, 5minuteinsure.com, utilizes AI and data mining, to provide competitive online insurance quotes within minutes to everyday consumers seeking to purchase auto, home, and life insurance. In addition, the Company operates its own portfolio of select retail “brick and mortar” insurance agencies which are leaders and pioneers in their respective regions throughout the United States, offering a wide variety of insurance products.
In addition to its insurance and Insurtech operations, Reliance operates EZRA International Group, its strategic growth platform focused on identifying, acquiring, and building majority or controlling stakes in high-growth technology companies. EZRA International Group is designed to complement Reliance’s core insurance business by expanding market reach and supporting long-term shareholder value creation through disciplined capital allocation and active ownership.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identifiable by the use of words such as “may,” “should,” “could,” “would,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “continue,” “seek,” “potential,” “target,” or similar expressions.
Forward-looking statements in this press release include, without limitation, statements regarding: the Company’s expected pathway to increase its ownership in Enquantum Ltd. to a 51% fully diluted controlling interest pursuant to the definitive agreement; the timing, funding and completion of future milestone-based tranche investments; the Company’s anticipated ability to obtain majority governance rights upon achievement of specified milestones; the development, performance, scalability and commercialization of Enquantum’s post-quantum cryptographic technology; the anticipated demand for, and timing of, migration to quantum-resilient encryption standards; the size, growth and evolution of the post-quantum cybersecurity market; the Company’s ability to integrate Enquantum within EZRA International Group and execute its Scale51 operating model; the expected strategic, operational and financial benefits of the transaction; and the Company’s broader capital allocation strategy and growth objectives.
These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties, many of which are beyond the Company’s control. Such risks and uncertainties include, without limitation: the risk that future milestone conditions are not achieved or are delayed; the risk that the Company is unable to fund future tranche investments on anticipated terms or timelines; the risk that the Company does not ultimately obtain majority ownership or governance control; risks related to the development, validation, performance, regulatory acceptance, commercialization or market adoption of Enquantum’s technology; the risk that post-quantum standards adoption or infrastructure migration occurs more slowly or differently than anticipated; integration, execution and scaling challenges associated with supporting an early-stage technology company; the risk that anticipated synergies or strategic benefits are not realized on expected timelines or at all; intellectual property, cybersecurity, regulatory and data protection risks; the Company’s ability to access capital on acceptable terms or at all; and general economic, market, interest rate and geopolitical conditions.
Actual results may differ materially from those expressed or implied by these forward-looking statements. Additional information regarding factors that may cause actual results to differ materially is included under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as amended, and in the Company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.
